Fig. 6

Combination study of sv6D and paclitaxel. a Female C57BL/6 mice were implanted with ID8 ovarian cancer cell line. In this experiment, progression of disease was aggressive, with a median survival of 65 days. Body weights of mice on day 58, after two weeks of alternate-day subcutaneous treatment with sv6D (0.1 nmole/g) or 3 intraperitoneal doses (days 45, 47 and 49) of 18 μg/g paclitaxel in cremophor. Analysis of these data by t test with Welch’s correction for unequal variance when applicable indicates ρ = < 0.05 for sv6D vs. PBS or no treatment and ρ = < 0.05 for paclitaxel vs PBS or no treatment. There was no statistical difference between the effects of paclitaxel and sv6D. b Alternate-day injections of sv6D were initiated on day 50 with peptide alone or on day 100 to mice that were previously treated with paclitaxel between day 45 and 49. The figure shows weights of mice on day 121. Analysis of the data set by t test indicated that paclitaxel vs. PBs ρ = < 0.05; paclitaxel vs. sv6D was not different, and paclitaxel vs. paclitaxel plus sv6D ρ = < 0.05. c Kaplan-Meier survival curves for mice treated with paclitaxel, sv6D or a combination of the two in which alternate-day subcutaneous injections of sv6D was started 50 days after paclitaxel treatment. Mantel-Cox log-rank test, p _{(sv6D vs. PBS)} = < 0.0001. Paclitaxel, brown; sv6D from day 45, blue; paclitaxel plus sv6D from day 100, purple; cremophor, yellow; PBS, black